Shelley Schendel, DO
Pulmonary Disease · Shelby Township, MINPI 1215050570
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for pulmonary disease clinicians in MI, where the typical reported total is $1,164.
Across 79 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$298
- Johnson & Johnson$286
- GSK$183
- Sunovion Pharmaceuticals Inc.$130
- Boehringer Ingelheim$110
- Philips North America LLC$71
- plus $474 from 13 others
Across 2 payments — averaging $8050.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$16K
What the payments were for
- Food & beverage$1,552100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $298 |
| Johnson & Johnson(2 entities) | 5 | $286 |
| GSK | 11 | $183 |
| Sunovion Pharmaceuticals Inc. | 11 | $130 |
| Boehringer Ingelheim | 5 | $110 |
| Philips North America LLC | 4 | $71 |
| Actelion Pharmaceuticals US, Inc. | 3 | $67 |
| E.r. Squibb & Sons, L.L.C. | 1 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $52 |
| Grifols USA, LLC | 3 | $51 |
| Insmed, Inc. | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| United Therapeutics Corporation | 1 | $24 |
| Sanofi | 1 | $21 |
| Harmony Biosciences LLC | 1 | $16 |
| Electromed, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
How this compares
$1,552 in reported general payments places this provider in the 50th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 439 | $527,834 |
| XolairOmalizumab | 13 | $71,114 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 69 | $59,996 |
| Dupixent SyringeDupilumab | 14 | $53,379 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $30,303 |
| Spiriva RespimatTiotropium Bromide | 31 | $30,196 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $24,917 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $20,417 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 290 | $18,202 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $15,602 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $13,582 |
| Tiotropium Bromide | 18 | $13,303 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $9,450 |
| Spiriva HandihalerTiotropium Bromide | 14 | $8,987 |
| Atrovent HfaIpratropium Bromide | 11 | $8,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $183 | $583,054522 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Airsupra | $298 | $81,585121 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $110 | $64,19567 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Shelby Township
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
- Podduturu ReddyPort Huron$324K
- Samuel AllenTroy$287K
- Daniel MaxwellAlpena$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.